Fujioka T, Shiraishi M, Tanji S, Koike H, Suzuki K, Kumagai K, Aoki H, Sakuma Y, Ohhori T, Kubo T
Department of Urology, Iwate Medical University School of Medicine.
Hinyokika Kiyo. 1989 Feb;35(2):253-7.
In 38 patients with superficial bladder, local immunotherapy with streptococcal preparation OK-432 has been performed. We investigated whether OK-432 was an effective biological response modifier (BRM) against bladder tumors or not, and the relationship between the common antigens which OK-432 shared with the tumors, and antitumor effects of OK-432. In six out of 28 patients treated by intravesical instillation, and three out of 10 cases treated by intratumor injection, tumors were eliminated endoscopically. In the other patients, the tumors did not change. The PAP study using an anti-OK-432 antibody, showed a positive reaction in 66.7% of the instillation cases and in 40.0% in the injection cases. In 66.7% of the patients with the common antigens treated by the instillation and in 75.0% of patients with the antigens treated by the injection, tumors were eliminated. However, the PAP study showed a positive reaction in 9.1% of the no-change cases treated by the instillation and in 14.3% out of the no-change cases treated by the injection. We concluded that OK-432 was a favorable BRM for topical immunotherapy against bladder tumor and the presence of the common antigens between OK-432 and tumor may enhance the immune response of patients and promote tumor regression.
对38例浅表性膀胱癌患者进行了链球菌制剂OK-432的局部免疫治疗。我们研究了OK-432是否是一种有效的抗膀胱肿瘤生物反应调节剂（BRM），以及OK-432与肿瘤共有的共同抗原之间的关系，以及OK-432的抗肿瘤作用。在28例经膀胱内灌注治疗的患者中，有6例，在10例经肿瘤内注射治疗的患者中，有3例，肿瘤在内镜下被清除。在其他患者中，肿瘤没有变化。使用抗OK-432抗体的PAP研究显示，灌注病例中有66.7%呈阳性反应，注射病例中有40.0%呈阳性反应。在66.7%的经灌注治疗的有共同抗原的患者和75.0%的经注射治疗的有抗原的患者中，肿瘤被清除。然而，PAP研究显示，灌注治疗的无变化病例中有9.1%呈阳性反应，注射治疗的无变化病例中有14.3%呈阳性反应。我们得出结论，OK-432是一种用于膀胱肿瘤局部免疫治疗的良好BRM，OK-432与肿瘤之间共同抗原的存在可能增强患者的免疫反应并促进肿瘤消退。
